Xencor Inc.
Xencor, Inc. (NASDAQ: XENC) develops patented engineered monoclonal antibodies for cancer, autoimmune and allergic diseases, with approved products Ultomiris and Monjuvi, a bispecific pipeline, supported by collaborations with Genentech, Novartis and Amgen.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Research Services
- Employees: 250
- HQ: Pasadena
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.